0001683168-21-001893.txt : 20210511 0001683168-21-001893.hdr.sgml : 20210511 20210511170036 ACCESSION NUMBER: 0001683168-21-001893 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37937 FILM NUMBER: 21912239 BUSINESS ADDRESS: STREET 1: 40 SPEEN STREET, SUITE 102 CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 40 SPEEN STREET, SUITE 102 CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 10-Q 1 xenetic_10q-033121.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37937

XENETIC BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of

incorporation or organization)

45-2952962

(IRS Employer

Identification No.)

40 Speen Street, Suite 102

Framingham, Massachusetts 01701

(Address of principal executive offices and zip code)

781-778-7720

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	XBIO	The Nasdaq Stock Market LLC
Purchase Warrants	XBIOW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days): Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2): Yes ☐ No ☒

As of May 7, 2021, the number of outstanding shares of the registrant’s common stock was 8,746,692.

XENETIC BIOSCIENCES, INC.

FORM 10-Q

QUARTERLY PERIOD ENDED MARCH 31, 2021

PART I	FINANCIAL INFORMATION

Item 1	Condensed Consolidated Financial Statements:	3

	Condensed Consolidated Balance Sheets as of March 31, 2021 (Unaudited) and December 31, 2020	3

	Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2021 and 2020	4

	Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) for the three months ended March 31, 2021 and 2020	5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2021 and 2020	7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3	Quantitative and Qualitative Disclosures About Market Risk	20

Item 4	Controls and Procedures	21

PART II	OTHER INFORMATION

Item 1	Legal Proceedings	22

Item 1A	Risk Factors	22

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3	Defaults Upon Senior Securities	22

Item 4	Mine Safety Disclosures	22

Item 5	Other Information	22

Item 6	Exhibits	23

Signatures		24

PART I – FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2021			December 31, 2020
		(Unaudited)

ASSETS
Current assets:
Cash	$	10,008,364		$	11,527,552
Prepaid expenses and other		1,027,749			841,958
Total current assets		11,036,113			12,369,510

Other assets		725,509			809,985
Total assets	$	11,761,622		$	13,179,495

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	207,811		$	327,396
Accrued expenses and other current liabilities		590,380			609,532
Total current liabilities		798,191			936,928

Other long-term liabilities		17,568			27,043
Total liabilities		815,759			963,971

Commitments (Note 11)
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized
Series B, $0.001 par value: 1,804,394 shares issued and outstanding as of March 31, 2021 and December 31, 2020		1,804			1,804
Series A, $0.001 par value: 970,000 shares issued and outstanding as of March 31, 2021 and December 31, 2020		970			970
Common stock, $0.001 par value; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of March 31, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of March 31, 2021 and December 31, 2020, respectively		8,772			8,771
Additional paid in capital		194,209,794			194,133,511
Accumulated deficit		(178,248,031	)		(176,902,086	)
Accumulated other comprehensive income		253,734			253,734
Treasury stock		(5,281,180	)		(5,281,180	)
Total stockholders' equity		10,945,863			12,215,524
Total liabilities and stockholders' equity	$	11,761,622		$	13,179,495

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended March 31,
	2021			2020

Revenue:
Royalty revenue	$	191,216		$	56,749
Total revenue		191,216			56,749

Operating costs and expenses:
Research and development		(629,729	)		(359,651	)
General and administrative		(930,578	)		(927,880	)
Total operating costs and expenses		(1,560,307	)		(1,287,531	)
Loss from operations		(1,369,091	)		(1,230,782	)

Other income (expense):
Other income (expense)		884			(134	)
Interest income		22,262			51,487
Total other income		23,146			51,353

Net loss	$	(1,345,945	)	$	(1,179,429	)

Basic and diluted loss per share	$	(0.15	)	$	(0.19	)

Weighted-average shares of common stock outstanding, basic and diluted		8,746,263			6,233,331

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

THREE MONTHS ENDED MARCH 31, 2021

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity

Balance as of January 1, 2021		2,774,394	$	2,774		8,772,198	$	8,771	$	194,133,511		$	(176,902,086	)	$	253,734	$	(5,281,180	)	$	12,215,524
Share-based expense		–		–		–		–		76,284			–			–		–			76,284
Exercise of purchase warrants		–		–		1,485		1		(1	)		–			–		–			–
Net loss		–		–		–		–		–			(1,345,945	)		–		–			(1,345,945	)
Balance as of March 31, 2021		2,774,394	$	2,774		8,773,683	$	8,772	$	194,209,794		$	(178,248,031	)	$	253,734	$	(5,281,180	)	$	10,945,863

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

THREE MONTHS ENDED MARCH 31, 2020

	Preferred Stock				Common Stock										Accumulated
	Number of Shares		Par Value ($0.001)		Number of Shares		Par Value ($0.001)		Additional Paid in Capital			Accumulated Deficit			Other Comprehensive Income		Treasury Stock			Total Stockholders' Equity

Balance as of January 1, 2020		2,774,394	$	2,774		6,092,432	$	6,092	$	188,240,451		$	(166,008,620	)	$	253,734	$	(5,281,180	)	$	17,213,251
Share-based expense		–		–		–		–		165,598			–			–		–			165,598
Exercise of purchase warrants		–		–		219,474		219		(219	)		–			–		–			–
Net loss		–		–		–		–		–			(1,179,429	)		–		–			(1,179,429	)
Balance as of March 31, 2020		2,774,394	$	2,774		6,311,906	$	6,311	$	188,405,830		$	(167,188,049	)	$	253,734	$	(5,281,180	)	$	16,199,420

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,345,945	)	$	(1,179,429	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		–			591
Amortization of right of use asset		8,413			6,824
Share-based expense		76,284			165,598
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(109,728	)		(86,448	)
Accounts payable, accrued expenses and other liabilities		(148,212	)		92,144
Net cash used in operating activities		(1,519,188	)		(1,000,720	)

Net change in cash		(1,519,188	)		(1,000,720	)
Cash at beginning of period		11,527,552			10,367,920

Cash at end of period	$	10,008,364		$	9,367,200

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	–		$	–

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock from cashless exercise of purchase warrants	$	1		$	219

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

XENETIC BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.	The Company

Background

Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART^™, a personalized Chimeric Antigen Receptor (“CAR”) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (“Scripps Research”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.

Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen^®, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid to prolong a drug’s circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics.

As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.

The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated.

Going Concern and Management’s Plan

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On December 4, 2020, the Company closed on a $6.0 million registered direct offering of the Company’s common stock, par value $0.001 resulting in $5.4 million of net proceeds to the Company. The Company believes that this financing, coupled with the Company’s existing resources, will be adequate to fund the Company’s operations through May 2022. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its clinical development programs, its ability to identify and enter into licensing or other strategic arrangements, and factors related to financial, economic and market conditions, many of which are beyond its control.

2.	Impact of COVID-19

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus, or COVID-19. The pandemic has significantly affected economic conditions in the U.S., accelerating during the first half of March 2020 and continuing into 2021, as federal, state and local governments react to the public health crisis with mitigation measures, creating significant uncertainties in the U.S. economy. The Company continues to evaluate the effects of the COVID-19 pandemic on its business and while there has been no significant impact to the Company’s operations to date, the Company at this time is uncertain of the impact this event may have on the Company’s future operations. The extent to which the COVID-19 pandemic affects our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict, and such uncertainty is expected to continue for some time.

3.	Summary of Significant Accounting Policies

Preparation of Interim Financial Statements

The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.

Principles of Consolidation

The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share

The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.

For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recent Accounting Standards

In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

4.	Significant Strategic Collaborations

The Company has entered into various research, development, license and supply agreements with Takeda Pharmaceuticals Co. Ltd. (“Takeda”), Serum Institute of India (“Serum Institute”), Pharmsynthez and SynBio LLC (“SynBio”), a wholly owned subsidiary of Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2021. In October 2017, the Company granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to the Company’s PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. Royalty payments of approximately $0.2 million and $0.1 million were recorded as revenue by the Company during the three months ended March 31, 2021 and 2020, respectively. The Company’s policy is to recognize royalty payments as revenue when they are reliably measurable, which is upon receipt of reports from Takeda. The Company receives these reports in the quarter subsequent to the actual sublicensee sales. There were no remaining performance obligations and all other revenue recognition criteria were met. No amounts were recognized as revenue related to the Serum Institute, Pharmsynthez or SynBio agreements during the three months ended March 31, 2021 and 2020, respectively.

On May 15, 2020, the Company and Scripps Research entered into a Research Funding and Option Agreement (the “Scripps Agreement”), pursuant to which the Company has agreed to provide Scripps Research an aggregate of up to $3.0 million to fund research relating to advancing the pre-clinical development of XCART. The research funding is payable by the Company to Scripps Research on a quarterly basis in accordance with a negotiated budget, which provides for an initial payment of approximately $300,000 on the date of the Scripps Agreement and subsequent quarterly payments of approximately $300,000 over a 27-month period. Under the Scripps Agreement, Scripps Research has granted the Company a license within the Field (as defined in the Scripps Agreement) to any Patent Rights or Technology (as defined in the Scripps Agreement) under the terms of that certain license agreement with Scripps Research, dated February 25, 2019, assigned to the Company on March 1, 2019. Additionally, the Company has the option to acquire a worldwide exclusive license to Scripps Research’s rights in the Technology or Patent Rights not already licensed to the Company, as well as a non-exclusive, royalty-free, non-transferrable license to make and use Scripps Research Technology (as defined in the Scripps Agreement) solely for the Company’s internal research purposes during the performance of the research program contemplated by the Scripps Agreement. The Company has paid $1.2 million to Scripps Research under this agreement through March 31, 2021. As of March 31, 2021 and December 31, 2020, approximately $0.2 million has been recognized as an advance payment under this agreement and is included in Prepaid expenses and other current assets.

5.	Property and Equipment, net

Property and equipment, net consists of the following:

	March 31, 2021			December 31, 2020
Office and computer equipment	$	42,289		$	42,289
Furniture and fixtures		14,738			14,738
Property and equipment – at cost		57,027			57,027
Less accumulated depreciation		(57,027	)		(57,027	)
Property and equipment – net	$	–		$	–

Depreciation expense was approximately $1,000 for the three months ended March 31, 2020. There was no depreciation expense for the three months ended March 31, 2021.

6.	Indefinite-Lived Intangible Assets

The Company’s indefinite-lived intangible asset, OncoHist, is in-process research and development (“IPR&D”) relating to the Company’s business combination with SymbioTec in 2012. IPR&D is tested for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable, although it is to be tested at least annually until the project is completed or abandoned. The Company completed an impairment analysis of the IPR&D during 2020 and concluded that the following factors indicated that the IPR&D was impaired: a decision by management to delay indefinitely any further development of the IPR&D and to not support the underlying intellectual property; the failure to sell or license the IPR&D to a third party; and the reduction in market capitalization. The Company recorded an asset impairment charge of $9.2 million during the third quarter of 2020 representing the excess of the IPR&D asset’s carrying value over its estimated fair value. A reconciliation of the change in the carrying value of Indefinite-Lived Intangible Assets is as follows:

Balance as of January 1, 2020	$	9,243,128
Impairment		(9,243,128	)
Balance as of December 31, 2020	$	–

7.	Fair Value Measurements

Accounting Standards Codification Topic 820, Fair Value Measurement, defines fair value as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. The carrying amount of certain of the Company’s financial instruments approximate fair value due to their short maturities. As of March 31, 2021 and December 31, 2020, the carrying amounts of the Company’s financial instruments approximates fair value due to their short maturities. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three months ended March 31, 2021 and 2020.

8.	Stockholders’ Equity

Warrants

In connection with certain of the Company’s collaboration agreements and consulting arrangements, the Company has issued warrants to purchase shares of common stock as payment for services. As of March 31, 2021 and December 31, 2020, collaboration warrants to purchase 30,307 shares of common stock were outstanding. The outstanding warrants as of March 31, 2021 have an average weighted exercise price of $124.74 per share and expiration dates ranging from April 2021 through May 2021. No collaboration warrants were granted or exercised and none expired in connection with collaboration or consulting services during the three months ended March 31, 2021 and 2020, respectively.

In addition, the Company has outstanding warrants to purchase an aggregate of 347,505 and 378,453 shares of common stock in connection with debt and equity financing arrangements as of March 31, 2021 and December 31, 2020, respectively. As of March 31, 2021, these warrants have an average weighted exercise price of $36.74 per share and expiration dates ranging from July 2021 through September 2026. No debt and equity financing warrants were granted during the three months ended March 31, 2021 and 2020. During the three months ended March 31, 2021 and 2020, debt and equity financing warrants to purchase approximately 1,485 and 0.2 million shares of common stock, respectively, were exercised on a cashless one-for-one basis. In addition, approximately 29,000 debt and equity warrants expired during the three months ended March 31, 2021. No debt and equity warrants expired during the three months ended March 31, 2020.

9.	Share-Based Expense

Total share-based expense related to stock options and restricted stock units (“RSUs”) was approximately $0.1 and $0.2 million during the three months ended March 31, 2021 and 2020, respectively.

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:

	Three Months Ended March 31,
	2021		2020
Research and development expenses	$	10,710	$	13,358
General and administrative expenses		65,574		152,240
	$	76,284	$	165,598

Employee Stock Options

During the three months ended March 31, 2021, the Company granted 200,000 stock option awards to purchase shares of common stock. The weighted average grant date fair value per option share was $2.34. Key assumptions used in the Black-Scholes option pricing model for options granted during the three months ending March 31, 2021 were the Company’s stock price, a risk free rate of 1.08%, an expected life of 5.88 years and an expected volatility rate of 134.47%. There were no employee stock options or RSUs granted or exercised during the three months ended March 31, 2020. The Company recognized a total of approximately $0.1 million and $0.2 million of compensation expense related to employee stock options during the three months ended March 31, 2021 and 2020, respectively.

Non-Employee Stock Options

There were no non-employee stock options granted or exercised and none expired during the three months ended March 31, 2021 and 2020, respectively. The Company did not recognize any expense related to non-employee stock options during the three months ended March 31, 2021. The Company recognized approximately $4,000 of expense during the three months ended March 31, 2020.

10.

Income Taxes

During the three months ended March 31, 2021 and 2020, there was no provision for income taxes as the Company incurred losses during both periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company records a valuation allowance against its deferred tax assets as the Company believes it is more likely than not the deferred tax assets will not be realized. The valuation allowance against deferred tax assets was approximately $29.9 million and $29.6 million as of March 31, 2021 and December 31, 2020, respectively.

As of March 31, 2021 and December 31, 2020, the Company did not record any unrecognized tax positions.

11.

Commitments

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

	Three Months Ended March 31,
	2021
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	8,413

Supplemental balance sheet information related to our operating leases are as follows:

	Balance Sheet Classification	March 31, 2021
Right-of-use assets - ST	Prepaid expenses and other	$	36,545
Right-of-use assets - LT	Other assets	$	17,568
Current lease liabilities	Accrued expenses and other current liabilities	$	36,545
Non-current lease liabilities	Other long-term liabilities	$	17,568

12.

Related Party Transactions

The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (as well as SynBio), each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 as amended on April 28, 2021.

During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the Company’s co-development agreement with SynBio. The Pharmsynthez Loan had a term of 15-months and accrued interest at a rate of 10% per annum. The Pharmsynthez Loan is guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and is secured by all of the equity interests of the Company owned by Pharmsynthez and SynBio. The Company recognized approximately $12,000 and $13,000 of interest income related to this loan during the three months ended March 31, 2021 and 2020, respectively.

Effective January 23, 2021, the Company entered into a First Amendment to Loan Agreement and Other Loan Documents with Pharmsynthez, Kevelt and SynBio (the “Pharmsynthez Loan Extension”) to modify the repayment terms and maturity of the Pharmsynthez Loan to January 2022. The terms of the Pharmsynthez Loan Extension called for two (2) equal monthly principal payments of $25,000 in each of January 23, 2021 and February 28, 2021 and the payment of all outstanding accrued interest in six (6) equal monthly installments from January 31, 2021 through June 30, 2021. In addition, the Pharmsynthez Loan Extension requires monthly interest payments and the repayment of the remaining principal amount in six (6) equal monthly installments from July 2021 through January 2022. All other terms of the Pharmsynthez Loan remain in effect. As of March 31, 2021, approximately $0.5 million was included in Prepaid expenses and other on the condensed consolidated balance sheet. As of December 31, 2020, approximately $0.5 million was classified within Prepaid expenses and other and approximately $0.1 million was classified within Other assets on the consolidated balance sheet.

During the third quarter of 2019, the Company entered into a Sponsored Research Agreement with Pharmsynthez (the “SRA”) related to experiments identified by the Company to support its efforts for initial tech transfer of the XCART methods to a future academic collaborator. Under the agreement, the Company made a $350,000 payment to Pharmsynthez during the third quarter of 2019, which was refundable on pro rata basis if the project is terminated prematurely as a result of Pharmsynthez failing to perform the work. On June 12, 2020, the Company and Pharmsynthez entered into a Master Services Agreement (“MSA”) to advance the development of the Company’s XCART technology for B-cell malignancies. The MSA terminated and superseded the SRA. The Company expensed approximately $0.1 million related to work performed under these agreements during the three months ended March 31, 2021 and 2020. As of March 31, 2021, approximately $30,000 was accrued and included in Accrued expenses and other current liabilities on the condensed consolidated balance sheet. As of December 31, 2020, approximately $25,000 was recorded as an advanced payment and included in Prepaid expenses and other on the consolidated balance sheet.

Under the MSA, Pharmsynthez agreed to provide services pursuant to work orders agreed upon by the parties from time to time, which services include, but are not limited to, acting as the Company’s primary contract research organization to assist in managing collaborations with multiple academic institutions in Russia and Belarus. The Company is required to pay reasonable fees, expenses and pass-through costs incurred by Pharmsynthez in providing the services in accordance with a budget and payment terms set forth in each work order. Additionally, in the event that a work order provides for milestone payments, the Company is required to make such payments to Pharmsynthez, or third party service providers designated by Pharmsynthez, in accordance with the terms set forth in the work order, which milestone payments may be made, at the sole discretion of the Company, in cash or shares of the Company’s common stock.

The Company and Pharmsynthez executed a work order on June 12, 2020 (the “Work Order”) under the MSA pursuant to which Pharmsynthez agreed to conduct a Stage 1 study of the Company’s XCART technology under the research program as set forth in the Work Order. The activities to be performed under the Work Order are expected to take approximately 20 months unless earlier terminated in accordance with the MSA. Under the terms of the Work Order, the Company paid Pharmsynthez $51,000 as an initial payment for trial startup costs, which amount was credited against the amounts paid under the SRA. The Work Order provides for additional pass-through costs to be invoiced by Pharmsynthez upon execution of contracts with third party sites, which will be further credited against the SRA. The total cost under the Work Order is currently estimated to be approximately $1.8 million. Through March 31, 2021, all costs incurred under the MSA were credited against the amounts paid under the SRA. Additionally, the Work Order provides for milestone payments of up to an aggregate of $1,050,000, or, in the Company’s sole discretion, up to an aggregate of 1,000,000 shares of the Company’s common stock, to be paid or issued, as applicable, by the Company upon achievement of milestones associated with completion of early stages of the research program as set forth in the Work Order. As of March 31, 2021, approximately $0.1 million of milestone payments has been paid.

13.

Subsequent Events

The Company performed a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined that there were no such events requiring recognition or disclosure in the financial statements.

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, future revenues, projected costs, prospects and our objectives for future operations, are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the anticipated effects and duration of the novel coronavirus, or COVID-19, global pandemic and the responses thereto, including the pandemic’s impact on general economic and market conditions, as well as on our business, results of operations and financial condition; our plans to develop our proposed drug candidates; our expectations regarding the nature, timing and extent of clinical trials and proposed clinical trials including the timing of generating clinical data from these trials; our expectations regarding the timing for proposed submissions of regulatory filings, including but not limited to any Investigational New Drug filing or any New Drug Application; the nature, timing and extent of collaboration arrangements; the expected results pursuant to collaboration arrangements including the receipts of future payments that may arise pursuant to collaboration arrangements; the outcome of our plans to obtain regulatory approval of our drug candidates; the outcome of our plans for the commercialization of our drug candidates; our plans to address certain markets, engage third party manufacturers, and evaluate additional drug candidates for subsequent commercial development, and the likelihood and extent of competition to our drug candidates; the development of the XCART^™ Chimeric Antigen Receptor (“CAR”) T technology; our plans to apply the XCART technology to advance cell-based therapeutics by targeting the unique B cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas; our beliefs regarding the expected results of the XCART technology, including its potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells; and our anticipation that our primary focus will now be on advancing the XCART technology through regulatory approval and commercialization technology.

In some cases, these statements may be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, or “continue”, or the negative of such terms and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, we cannot guarantee future results, the levels of activity, performance or achievements. These statements involve known and unknown risks and uncertainties that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from those expressed or implied by forward-looking statements.

The Management’s Discussion and Analysis of Financial Condition and Results of Operations (the “MD&A”) should be read together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report. This Quarterly Report, including the MD&A, contains trend analysis and other forward-looking statements. Any statements in this Quarterly Report that are not statements of historical facts are forward-looking statements. These forward-looking statements made herein are based on our current expectations, involve a number of risks and uncertainties and should not be considered as guarantees of future performance.

Some factors that could cause actual results to differ materially include without limitation:


	·	our need to raise additional working capital in the future for the purpose of further developing our XCART technology and to continue as a going concern;
	·	our ability to finance our business;
	·	our ability to successfully execute, manage and integrate key acquisitions and mergers, including integration of the acquisition of the XCART technology;
	·	product development and commercialization risks, including our ability to successfully develop the XCART technology;
	·	the impact of adverse safety outcomes and clinical trial results for CAR-T cell therapies;
	·	our ability to secure and maintain a manufacturer for the XCART technology;
	·	our ability to successfully commercialize our current and future drug candidates;
	·	our ability to achieve milestone and other payments associated with our current and future co-development collaborations and strategic arrangements;
	·	the impact of new technologies on our drug candidates and our competition;
	·	changes in laws or regulations of governmental agencies;
	·	interruptions or cancellation of existing contracts;
	·	impact of competitive products and pricing;
	·	product demand and market acceptance and risks;
	·	the presence of competitors with greater financial resources;
	·	continued availability of supplies or materials used in manufacturing at the current prices;
	·	the ability of management to execute plans and motivate personnel in the execution of those plans;
	·	our ability to attract and retain key personnel;
	·	adverse publicity related to our products or the Company itself;
	·	adverse claims relating to our intellectual property;
	·	the adoption of new, or changes in, accounting principles;
	·	the costs inherent with complying with statutes and regulations applicable to public reporting companies, such as the Sarbanes-Oxley Act of 2002;
	·	other new lines of business that the Company may enter in the future;
	·	general economic and business conditions, as well as inflationary trends;
	·	the impact of natural disasters or public health emergencies, such as the COVID-19 global pandemic, on our financial condition and results of operations; and
	·	other factors set forth in the Risk Factors section of our Annual Report on Form 10-K and in subsequent filings with the Securities and Exchange Commission (“SEC”).

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in the forward-looking statements in this Quarterly Report. Other unknown or unpredictable factors also could have material adverse effects on our future results, including, but not limited to, those discussed in the section titled “Risk Factors.” The forward-looking statements in this Quarterly Report are made only as of the date of this Quarterly Report, and we do not undertake any obligation to publicly update any forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

BUSINESS OVERVIEW

We are a biopharmaceutical company focused on progressing XCART^™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. We are initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of the therapeutic assets targeting high-value oncology indications. The XCART technology, developed by the Scripps Research Institute (“Scripps Research”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells. We are currently advancing XCART preclinical efforts through strategic collaborations with Scripps Research and PJSC Pharmsynthez.

Additionally, we are leveraging our proprietary drug delivery platform, PolyXen^®, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid to prolong a drug’s circulating half-life and potentially improve other pharmacological properties.

We incorporate our patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what we believe will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics. Our drug candidates have resulted from our research activities or that of our collaborators and are in the development stage. As a result, we continue to commit a significant amount of our resources to our research and development activities and anticipate continuing to do so for the near future. To date, none of our drug candidates have received regulatory marketing authorization in the United States (“U.S.”) by the Food and Drug Administration nor in any other territories by any applicable agencies. We are receiving ongoing royalties pursuant to a license of our PolyXen technology to an industry partner.

We also have oncology therapeutic investigational drug candidate XBIO-101^™ (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. We commenced a Phase 2 trial under an Investigational New Drug filing in 2017, for the potential treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy, with the first patient dosed in October 2017. We closed patient enrollment in the trial in March 2019 as a result of slower than expected progress on the trial resulting from patient enrollment and retention challenges and have suspended further development of XBIO-101. We currently have no plans to continue development of XBIO-101.

Although we hold a broad patent portfolio, the focus of our internal development efforts during the three months ended March 31, 2021 was on advancing the development of our XCART platform technology and closing down our XBIO-101 Phase 2 trial.

Critical Accounting Estimates

The preparation of our financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue, costs and expenses during the reporting period. On an ongoing basis, we evaluate our estimates that are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. The result of these evaluations forms the basis for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results and outcomes could differ materially from our estimates, judgments and assumptions.

There has been no material change to our critical accounting estimates since those critical accounting estimates described in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021, as amended on April 28, 2021.

Effects of the COVID-19 Pandemic

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus, or COVID-19. The pandemic has significantly affected economic conditions in the U.S., accelerating during the first half of March 2020 and continuing into 2021, as federal, state and local governments react to the public health crisis with mitigation measures, creating significant uncertainties in the U.S. economy. We continue to evaluate the effects of the COVID-19 pandemic on our business, and while our operations were not materially affected during the three months ended March 31, 2021 despite social distancing and other measures taken in response to the pandemic, the ultimate impact of the COVID-19 pandemic on our results of operations and financial condition is dependent on future developments, including the duration of the pandemic and the related extent of its severity, as well as its impact on macroeconomic conditions, which are uncertain and cannot be predicted at this time. If the global response to contain the COVID-19 pandemic escalates further or is unsuccessful, or if governmental decisions to ease pandemic related restrictions are ineffective, premature or counterproductive, we could experience a material adverse effect on our business, financial condition, results of operations and cash flows.

RESULTS OF OPERATIONS

Comparison of Quarter Ended March 31, 2021 and 2020

The comparison of our historical results of operations for the fiscal quarter ended March 31, 2021 to the fiscal quarter ended March 31, 2020 is as follows:

Description	Quarter Ended March 31, 2021			Quarter Ended March 31, 2020			Increase (Decrease)			Percentage Change
Revenues:
Royalty revenue	$	191,216		$	56,749		$	134,467			237.0
Operating costs and expenses:
Research and development		(629,729	)		(359,651	)		270,078			75.1
General and administrative		(930,578	)		(927,880	)		2,698			0.3
Total operating costs and expenses		(1,560,307	)		(1,287,531	)		272,776			21.2
Loss from operations		(1,369,091	)		(1,230,782	)		138,309			11.2
Other income (expense):
Other income (expense)		884			(134	)		1,018			759.7
Interest income		22,262			51,487			(29,225	)		(56.8	)

Net loss	$	(1,345,945	)	$	(1,179,429	)	$	(166,516	)		14.1

Revenue

Revenue for the three months ended March 31, 2021 increased by $0.1 million, or 237.0%, to $0.2 million from approximately $0.1 million for the three months ended March 31, 2020. This increase represents an increase in royalty revenue related to our sublicense agreement with Takeda Pharmaceuticals Co. Ltd. as compared to the same period in 2020 as the sublicensee continued its worldwide launch of the product.

Research and Development Expenses

Research & development (“R&D”) expenses for the three months ended March 31, 2021 increased by $0.3 million, or 75.1%, to $0.6 million from $0.4 million in the comparable quarter in 2020. The table below sets forth the R&D costs incurred by the Company by category of expense for the quarters ended March 31, 2021 and 2020:

	Quarter Ended
Category of Expense	March 31, 2021		March 31, 2020
Outside services and contract research organizations	$	452,625	$	223,622
Salaries and wages		130,047		89,842
Share-based expense		10,710		13,358
Other		36,347		32,829
Total research and development expense	$	629,729	$	359,651

The increase in outside services and contract research organizations expense was primarily due to increased spending related to our XCART platform technology during the three months ended March 31, 2021 as compared to the same period in the prior year. Costs related to our XCART program were higher in 2021 as compared to the same period in 2020 as we continued to invest in our pre-clinical developments efforts. This increase was partially offset by a decrease in spending on our XBIO-101 Phase 2 clinical trial, which was closed during the first quarter of 2021. Salaries and wages increased during the three months ended March 31, 2021 due to slightly higher employee related costs, which was partially offset by lower share-based expense.

General and Administrative Expenses

General and administrative expenses for both the three months ended March 31, 2021 and 2020 was approximately $0.9 million. Increases in consulting and employee related costs during the three months ended March 31, 2021 compared to the same period in 2020 were substantially offset by lower share-based expense and legal and accounting costs.

Other Income (Expense)

Other income was approximately $900 for the three months ended March 31, 2021 compared to approximately $100 of other expense for the same period in 2020. This increase in other income was primarily related to changes in foreign currency exchange rates during the three months ended March 31, 2021 as compared to the same period in 2020.

Interest Income

Interest income decreased to approximately $22,000 during the three months ended March 31, 2021 as compared to approximately $51,000 for the same period in the prior year. This decrease is primarily due to a decrease in interest income on invested funds due to lower interest rates during the first quarter of 2021 compared to the same period in 2020.

Liquidity and Capital Resources

We incurred a net loss of approximately $1.3 million for the three months ended March 31, 2021. We had an accumulated deficit of approximately $178.2 million at March 31, 2021 as compared to an accumulated deficit of approximately $176.9 million at December 31, 2020. Working capital was approximately $10.2 million at March 31, 2021 and $11.4 million at December 31, 2020, respectively. During the three months ended March 31, 2021, our working capital decreased by $1.2 million due to our net loss for the three months ended March 31, 2021. We expect to continue incurring losses for the foreseeable future and may need to raise additional capital or pursue other strategic alternatives in the long-term in order to continue the pursuit of our business plan.

Our principal source of liquidity consists of cash. At March 31, 2021, we had approximately $10.0 million in cash and $0.8 million in current liabilities. At December 31, 2020, we had approximately $11.5 million in cash and $0.9 million in current liabilities. We have historically relied upon sales of our equity securities to fund our operations. We expect the majority of our funding through equity or equity-linked instruments, debt financings, corporate collaborations, related party funding and/or licensing agreements to continue as a trend for the foreseeable future.

Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. We have incurred substantial losses since our inception, and we expect to continue to incur operating losses in the near-term. These factors raise substantial doubt about our ability to continue as a going concern. We believe that we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On December 4, 2020, we closed on a $6.0 million registered direct Common Stock offering resulting in $5.4 million of net proceeds to us. We believe that this financing, coupled with our existing resources, will be adequate to fund our operations through May 2022. However, we anticipate we may need additional capital in the long-term to pursue our business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in our clinical development programs, our ability to identify and enter into licensing or other strategic arrangements, and factors related to financial, economic and market conditions, many of which are beyond our control.

Cash Flows from Operating Activities

Cash flows used in operating activities for the three months ended March 31, 2021 totaled approximately $1.5 million, which was primarily due to our net loss for the period, partially offset by non-cash charges associated with share-based expense. Cash flows used in operating activities for the three months ended March 31, 2020 totaled approximately $1.0 million, which was primarily due to our net loss for the period, offset by non-cash charges associated with share-based expense.

Cash Flows from Investing Activities

There were no cash flows from investing activities for the three months ended March 31, 2021 and 2020.

Cash Flow from Financing Activities

There were no cash flows from financing activities for the three months ended March 31, 2021 and 2020.

Contractual Obligations and Commitments

As of March 31, 2021, there were no material changes in our contractual obligations and commitments from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021.

Off Balance Sheet Arrangements

We do not have any off-balance sheet financing arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, change in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Recent Accounting Standards

See Note 3 in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021 for a discussion of recent accounting standards.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates. There have been no material changes in our critical accounting policies from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021, as amended on April 28, 2021.

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are not required to provide the information required by this Item because we are a “smaller reporting company” (as defined in Rule 12b-2 of the Exchange Act).

ITEM 4 – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this Quarterly Report.

Based on this evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report that would have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our financial condition or results of operations.

ITEM 1A – RISK FACTORS

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 as amended on April 28, 2021.

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 – DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 – MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5 – OTHER INFORMATION

None.

ITEM 6 – EXHIBITS

The following exhibits are incorporated herein by reference or filed as part of this report.

EXHIBIT NUMBER	DESCRIPTION
31.1*	Certification of Jeffrey F. Eisenberg, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of James Parslow, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certifications of Jeffrey F. Eisenberg, Principal Executive Officer, and James Parslow, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document - The instance document does not appear in the interactive data file because XBRL tags are embedded within the inline XBRL Document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

Exhibit 32.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, except as otherwise stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Xenetic Biosciences, Inc.


May 11, 2021	By:	/S/ JEFFREY F. EISENBERG
		Jeffrey F. Eisenberg
		Chief Executive Officer (Principal Executive Officer)

	By:	/S/ JAMES PARSLOW
		James Parslow Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 xenetic_ex3101.htm CERTIFICATION

EXHIBIT 31.1

I, Jeffrey F. Eisenberg, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2021

By: /s/ Jeffrey F. Eisenberg

Jeffrey F. Eisenberg
Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 xenetic_ex3102.htm CERTIFICATION

EXHIBIT 31.2

I, James Parslow, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Xenetic Biosciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2021

By: /s/ James Parslow

James Parslow
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)

EX-32.1 4 xenetic_ex3201.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic Biosciences, Inc. (the “Company”), and James Parslow, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2021, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 11, 2021

In Witness Whereof, the undersigned have set their hands hereto as of the 11th day of May 2021.

/s/ Jeffrey F. Eisenberg	/s/James Parslow
Jeffrey F. Eisenberg	James Parslow
Chief Executive Officer	Chief Financial Officer

“This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Xenetic Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”

EX-101.INS 5 xbio-20200331.xml XBRL INSTANCE FILE 0001534525 2020-12-31 0001534525 2019-12-31 0001534525 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001534525 xbio:OfficeAndComputerEquipmentMember 2020-12-31 0001534525 2021-01-01 2021-03-31 0001534525 2020-01-01 2020-03-31 0001534525 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001534525 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001534525 xbio:NonEmployeeStockOptionsMember 2020-01-01 2020-03-31 0001534525 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001534525 us-gaap:PreferredClassAMember 2020-12-31 0001534525 us-gaap:PreferredClassBMember 2020-12-31 0001534525 us-gaap:CommonStockMember 2019-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001534525 us-gaap:RetainedEarningsMember 2019-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001534525 us-gaap:TreasuryStockMember 2019-12-31 0001534525 us-gaap:PreferredStockMember 2019-12-31 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001534525 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001534525 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001534525 2021-05-07 0001534525 xbio:NonEmployeeStockOptionsMember 2021-01-01 2021-03-31 0001534525 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001534525 us-gaap:RoyaltyMember 2021-01-01 2021-03-31 0001534525 us-gaap:RoyaltyMember 2020-01-01 2020-03-31 0001534525 xbio:TakedaMember xbio:RoyaltyRevenueMember 2021-01-01 2021-03-31 0001534525 xbio:ColllaborationWarrantsMember 2020-12-31 0001534525 xbio:ColllaborationWarrantsMember 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:SponsoredResearchAgreementMember 2021-01-01 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:SponsoredResearchAgreementMember 2020-12-31 0001534525 xbio:PharmsynthezMember xbio:CoDevelopmentAgreementMember 2021-01-01 2021-03-31 0001534525 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001534525 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001534525 us-gaap:PreferredStockMember 2020-12-31 0001534525 us-gaap:CommonStockMember 2020-12-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001534525 us-gaap:RetainedEarningsMember 2020-12-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001534525 us-gaap:TreasuryStockMember 2020-12-31 0001534525 2021-03-31 0001534525 us-gaap:PreferredClassAMember 2021-03-31 0001534525 us-gaap:PreferredClassBMember 2021-03-31 0001534525 us-gaap:PreferredStockMember 2020-03-31 0001534525 us-gaap:CommonStockMember 2020-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001534525 us-gaap:RetainedEarningsMember 2020-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001534525 us-gaap:TreasuryStockMember 2020-03-31 0001534525 2020-03-31 0001534525 us-gaap:PreferredStockMember 2021-03-31 0001534525 us-gaap:CommonStockMember 2021-03-31 0001534525 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001534525 us-gaap:RetainedEarningsMember 2021-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001534525 us-gaap:TreasuryStockMember 2021-03-31 0001534525 xbio:OfficeAndComputerEquipmentMember 2021-03-31 0001534525 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001534525 xbio:DirectOfferingMember 2020-01-01 2020-12-04 0001534525 xbio:ColllaborationWarrantsMember 2021-01-01 2021-03-31 0001534525 xbio:ColllaborationWarrantsMember 2020-01-01 2020-03-31 0001534525 xbio:DebtAndEquityFinancingWarrantsMember 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:SponsoredResearchAgreementMember 2019-01-01 2019-12-31 0001534525 xbio:PharmsynthezMember xbio:SponsoredResearchAgreementMember 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:CoDevelopmentAgreementMember 2019-01-01 2019-12-31 0001534525 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001534525 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001534525 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001534525 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001534525 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:CoDevelopmentAgreementMember 2021-03-31 0001534525 xbio:TakedaMember xbio:RoyaltyRevenueMember 2020-01-01 2020-03-31 0001534525 xbio:SerumInstituteMember xbio:RoyaltyRevenueMember 2021-01-01 2021-03-31 0001534525 xbio:SerumInstituteMember xbio:RoyaltyRevenueMember 2020-01-01 2020-03-31 0001534525 xbio:SynBioMember xbio:RoyaltyRevenueMember 2021-01-01 2021-03-31 0001534525 xbio:SynBioMember xbio:RoyaltyRevenueMember 2020-01-01 2020-03-31 0001534525 xbio:ScrippsMember 2021-01-01 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:CoDevelopmentAgreementMember 2020-01-01 2020-03-31 0001534525 xbio:PharmsynthezMember xbio:SponsoredResearchAgreementMember xbio:PrepaidExpensesAndOtherMember 2021-03-31 0001534525 xbio:PharmsynthezMember xbio:SponsoredResearchAgreementMember xbio:PrepaidExpensesAndOtherMember 2020-12-31 0001534525 xbio:OncoHistMember 2020-07-01 2020-09-30 0001534525 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001534525 us-gaap:FairValueInputsLevel3Member 2020-03-31 0001534525 xbio:DebtAndEquityFinancingWarrantsMember 2020-12-31 0001534525 xbio:DebtAndEquityFinancingWarrantsMember 2021-01-01 2021-03-31 0001534525 xbio:DebtAndEquityFinancingWarrantsMember 2020-01-01 2020-03-31 0001534525 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 xbrli:shares iso4217:USD xbrli:pure iso4217:USD xbrli:shares 10-Q Xenetic Biosciences, Inc. XBIO 2021-03-31 false --12-31 2021 0001534525 Q1 Yes 8746692

0.001

970000

1804394

970000

1804394

970000

1804394

970000

1804394

57027

14738

42289

57027

42289

14738

57027

76284

165598

100000

4000

13358

10710

152240

65574

200000

100000

200000

true false

.001

0.001

8772198

8773683

8745207

8746692

10000000

191216

56749

191216

56749

200000

100000

Non-accelerated Filer false Yes NV 001-37937

841958

200000

1027749

200000

500000

629729

359651

100000

1200000

50000000

350000

124.74 124.74 36.74 36.74

8413

500000

30307

347505

378453

Common Stock, $0.001 par value per share April 2021 through May 2021 July 2021 through September 2026

29600000

29900000

36545

500000

0.10

936928

798191

327396

207811

13179495

11761622

809985

725509

12369510

11036113

11527552

10008364

27043

17568

963971

815759

13179495

11761622

5281180

253734

-176902086

-178248031

194133511

194209794

8771

8772

2774

970

1804

2774

970

1804

8746263

6233331

-0.15

-0.19

23146

51353

22262

51487

884

-134

-1369091

-1230782

1560307

1287531

930578

927880

1 219

11527552

10367920

10008364

9367200

-1519188

-1000720

-1519188

-1000720

-148212

92144

109728

86448

76284

165598

8413

6824

591

6092432

2774394

8772198

2774394

6311906

2774394

8773683

12215524

17213251

6092

188240451

-166008620

253734

-5281180

2774

8771

194133511

-176902086

253734

-5281180

10945863

2774

6311

188405830

-167188049

253734

-5281180

16199420

2774

8772

194209794

-178248031

253734

-5281180

76284

165598

76284

219474 1485

-1345945

-1179429

-1345945

219 -219 1 -1

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 33px">1.</td> <td style="text-align: justify">The Company </td></tr> </table>   Background   Xenetic Biosciences, Inc. (“Xenetic” or the “Company”), incorporated in the state of Nevada and based in Framingham, Massachusetts, is a biopharmaceutical company focused on progressing XCART™, a personalized Chimeric Antigen Receptor (“CAR”) T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The XCART technology, developed by the Scripps Research Institute (“Scripps Research”) in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.   Additionally, Xenetic is leveraging its proprietary drug delivery platform, PolyXen®, by partnering with biotechnology and pharmaceutical companies. PolyXen is an enabling platform technology which can be applied to protein or peptide therapeutics. It employs the natural polymer polysialic acid to prolong a drug’s circulating half-life and potentially improve other pharmacological properties. Xenetic incorporates its patented and proprietary technologies into a number of drug candidates currently under development with biotechnology and pharmaceutical industry collaborators to create what the Company believes will be the next-generation biologic drugs with improved pharmacological properties over existing therapeutics.   As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Xenetic,” the “Company,” “we” or “us” refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.   The Company, directly or indirectly, through its wholly-owned subsidiaries, Hesperix S.A. (“Hesperix”) and Xenetic Biosciences (U.K.) Limited (“Xenetic UK”), and the wholly-owned subsidiaries of Xenetic UK, Lipoxen Technologies Limited (“Lipoxen”), Xenetic Bioscience, Incorporated and SymbioTec, GmbH (“SymbioTec”), own various United States (“U.S.”) federal trademark registrations and applications, and unregistered trademarks and service marks, including but not limited to XCART, OncoHist™, PolyXen, ErepoXen™, and ImuXen™, which are used throughout this Quarterly Report. All other company and product names may be trademarks of the respective companies with which they are associated.   Going Concern and Management’s Plan   Management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company has incurred substantial losses since its inception and expects to continue to incur operating losses in the near-term. These factors raise substantial doubt about its ability to continue as a going concern. The Company believes that it has access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, related party funding, or other means to continue as a going concern. On December 4, 2020, the Company closed on a $6.0 million registered direct offering of the Company’s common stock, par value $0.001 resulting in $5.4 million of net proceeds to the Company. The Company believes that this financing, coupled with the Company’s existing resources, will be adequate to fund the Company’s operations through May 2022. However, the Company anticipates it may need additional capital in the long-term to pursue its business initiatives. The terms, timing and extent of any future financing will depend upon several factors, including the achievement of progress in its clinical development programs, its ability to identify and enter into licensing or other strategic arrangements, and factors related to financial, economic and market conditions, many of which are beyond its control.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 33px">3.</td> <td style="text-align: justify">Summary of Significant Accounting Policies </td></tr> </table>   Preparation of Interim Financial Statements   The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.    Principles of Consolidation   The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.   Basic and Diluted Net Loss per Share   The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.   For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.    Recent Accounting Standards   In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 33px">9.</td> <td style="text-align: justify">Share-Based Expense </td></tr> </table>   Total share-based expense related to stock options and restricted stock units (“RSUs”) was approximately $0.1 and $0.2 million during the three months ended March 31, 2021 and 2020, respectively.    Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">10,710</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,358</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">65,574</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">152,240</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">76,284</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">165,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Employee Stock Options   During the three months ended March 31, 2021, the Company granted 200,000 stock option awards to purchase shares of common stock. The weighted average grant date fair value per option share was $2.34. Key assumptions used in the Black-Scholes option pricing model for options granted during the three months ending March 31, 2021 were the Company’s stock price, a risk free rate of 1.08%, an expected life of 5.88 years and an expected volatility rate of 134.47%. There were no employee stock options or RSUs granted or exercised during the three months ended March 31, 2020. The Company recognized a total of approximately $0.1 million and $0.2 million of compensation expense related to employee stock options during the three months ended March 31, 2021 and 2020, respectively.   Non-Employee Stock Options   There were no non-employee stock options granted or exercised and none expired during the three months ended March 31, 2021 and 2020, respectively. The Company did not recognize any expense related to non-employee stock options during the three months ended March 31, 2021. The Company recognized approximately $4,000 of expense during the three months ended March 31, 2020.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="width: 33px">12.</td> <td style="text-align: justify">Related Party Transactions</td></tr> </table>   The Company has entered into various research, development, license and supply agreements with Serum Institute and Pharmsynthez (as well as SynBio), each a related party whose relationship has not materially changed from that disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 as amended on April 28, 2021.   During the fourth quarter of 2019, the Company entered into a loan agreement with Pharmsynthez (the “Pharmsynthez Loan”), pursuant to which the Company advanced Pharmsynthez an aggregate principal amount of up to $500,000 to be used for the development of a specific product under the Company’s co-development agreement with SynBio. The Pharmsynthez Loan had a term of 15-months and accrued interest at a rate of 10% per annum. The Pharmsynthez Loan is guaranteed by all of the operating subsidiaries of Pharmsynthez, including SynBio and AS Kevelt, and is secured by all of the equity interests of the Company owned by Pharmsynthez and SynBio. The Company recognized approximately $12,000 and $13,000 of interest income related to this loan during the three months ended March 31, 2021 and 2020, respectively.   Effective January 23, 2021, the Company entered into a First Amendment to Loan Agreement and Other Loan Documents with Pharmsynthez, Kevelt and SynBio (the “Pharmsynthez Loan Extension”) to modify the repayment terms and maturity of the Pharmsynthez Loan to January 2022. The terms of the Pharmsynthez Loan Extension called for two (2) equal monthly principal payments of $25,000 in each of January 23, 2021 and February 28, 2021 and the payment of all outstanding accrued interest in six (6) equal monthly installments from January 31, 2021 through June 30, 2021. In addition, the Pharmsynthez Loan Extension requires monthly interest payments and the repayment of the remaining principal amount in six (6) equal monthly installments from July 2021 through January 2022. All other terms of the Pharmsynthez Loan remain in effect. As of March 31, 2021, approximately $0.5 million was included in Prepaid expenses and other on the condensed consolidated balance sheet. As of December 31, 2020, approximately $0.5 million was classified within Prepaid expenses and other and approximately $0.1 million was classified within Other assets on the consolidated balance sheet.   During the third quarter of 2019, the Company entered into a Sponsored Research Agreement with Pharmsynthez (the “SRA”) related to experiments identified by the Company to support its efforts for initial tech transfer of the XCART methods to a future academic collaborator. Under the agreement, the Company made a $350,000 payment to Pharmsynthez during the third quarter of 2019, which was refundable on pro rata basis if the project is terminated prematurely as a result of Pharmsynthez failing to perform the work. On June 12, 2020, the Company and Pharmsynthez entered into a Master Services Agreement (“MSA”) to advance the development of the Company’s XCART technology for B-cell malignancies. The MSA terminated and superseded the SRA. The Company expensed approximately $0.1 million related to work performed under these agreements during the three months ended March 31, 2021 and 2020. As of March 31, 2021, approximately $30,000 was accrued and included in Accrued expenses and other current liabilities on the condensed consolidated balance sheet. As of December 31, 2020, approximately $25,000 was recorded as an advanced payment and included in Prepaid expenses and other on the consolidated balance sheet.   Under the MSA, Pharmsynthez agreed to provide services pursuant to work orders agreed upon by the parties from time to time, which services include, but are not limited to, acting as the Company’s primary contract research organization to assist in managing collaborations with multiple academic institutions in Russia and Belarus. The Company is required to pay reasonable fees, expenses and pass-through costs incurred by Pharmsynthez in providing the services in accordance with a budget and payment terms set forth in each work order. Additionally, in the event that a work order provides for milestone payments, the Company is required to make such payments to Pharmsynthez, or third party service providers designated by Pharmsynthez, in accordance with the terms set forth in the work order, which milestone payments may be made, at the sole discretion of the Company, in cash or shares of the Company’s common stock.   The Company and Pharmsynthez executed a work order on June 12, 2020 (the “Work Order”) under the MSA pursuant to which Pharmsynthez agreed to conduct a Stage 1 study of the Company’s XCART technology under the research program as set forth in the Work Order. The activities to be performed under the Work Order are expected to take approximately 20 months unless earlier terminated in accordance with the MSA. Under the terms of the Work Order, the Company paid Pharmsynthez $51,000 as an initial payment for trial startup costs, which amount was credited against the amounts paid under the SRA. The Work Order provides for additional pass-through costs to be invoiced by Pharmsynthez upon execution of contracts with third party sites, which will be further credited against the SRA. The total cost under the Work Order is currently estimated to be approximately $1.8 million. Through March 31, 2021, all costs incurred under the MSA were credited against the amounts paid under the SRA. Additionally, the Work Order provides for milestone payments of up to an aggregate of $1,050,000, or, in the Company’s sole discretion, up to an aggregate of 1,000,000 shares of the Company’s common stock, to be paid or issued, as applicable, by the Company upon achievement of milestones associated with completion of early stages of the research program as set forth in the Work Order. As of March 31, 2021, approximately $0.1 million of milestone payments has been paid.

Supplemental balance sheet information related to our operating leases are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance Sheet Classification</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify">Right-of-use assets - ST</td><td style="width: 2%"> </td> <td style="width: 41%; text-align: left">Prepaid expenses and other</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">36,545</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Right-of-use assets - LT</td><td> </td> <td style="text-align: left">Other assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,568</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Current lease liabilities</td><td> </td> <td style="text-align: left">Accrued expenses and other current liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36,545</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Non-current lease liabilities</td><td> </td> <td style="text-align: left">Other long-term liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">17,568</td><td style="text-align: left"> </td></tr></table>

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; background-color: White; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Three Months Ended March 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">Operating cash flow information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">8,413</td><td style="width: 1%; text-align: left"> </td></tr></table>

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Research and development expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">10,710</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,358</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">65,574</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">152,240</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">76,284</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">165,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

A reconciliation of the change in the carrying value of Indefinite-Lived Intangible Assets is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 58%">Balance as of January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">9,243,128</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Impairment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,243,128</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Property and equipment, net consists of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Office and computer equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">42,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">42,289</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Furniture and fixtures</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,738</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Property and equipment – at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,027</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(57,027</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(57,027</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment – net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Preparation of Interim Financial Statements   The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.

Principles of Consolidation   The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.

Basic and Diluted Net Loss per Share   The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.   For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.

Recent Accounting Standards   In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

5400000

9243128

9200000

9243128

1485

200000

2.34

0.0108

P5Y10M17D

1.3447

17568

12000

13000

100000

25000

29000

609532

590380

30000

EX-101.SCH 6 xbio-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. The Company link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Impact of COVID-19 link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Significant Strategic Collaborations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Commitments link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 13. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 3. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 5. Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 11. Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 1. The Company (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 4. Significant Strategic Collaborations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 5. Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 5. Property and Equipment, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 6. Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 6. Indefinite-Lived Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 7. Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 8. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 10. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 11. Commitments (Details - Cash flow Information) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 11. Commitments (Details - lease information) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 12. Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 xbio-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 xbio-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 xbio-20200331_lab.xml XBRL LABEL FILE Property, Plant and Equipment, Type [Axis] Furniture and Fixtures [Member] Office and Computer Equipment [Member] Award Type [Axis] Employee Stock Options [Member] Equity Components [Axis] Accumulated Deficit [Member] Non Employee Stock Options [Member] Common Stock [Member] Additional Paid-In Capital [Member] Class of Stock [Axis] Preferred Class A [Member] Preferred Class B [Member] Accumulated Other Comprehensive Income / Loss Treasury Stock [Member] Preferred Stock [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Restricted Stock Units (RSUs) [Member] Product Or Service [Axis] Royalty [Member] Counterparty Name [Axis] Takeda [Member] Royalty [Member] Colllaboration Warrants [Member] Related Party [Axis] Pharmsynthez [Member] Transaction Type [Axis] Sponsored Research Agreement [Member] Co-Development Agreement [Member] Common Stock Additional Paid-In Capital Retained Earnings / Accumulated Deficit Treasury Stock Direct Offering [Member] Debt and Equity Financing Warrants [Member] Serum Institute [Member] SynBio [Member] Scripps [Member] Balance Sheet Location [Axis] Prepaid expenses and other [Member] Indefinite-lived Intangible Assets [Axis] OncoHist [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Inputs Level 3 [Member] Cover [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Trading Symbol Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Current Reporting Status Entity Small Business Entity Emerging Growth Entity Transition Period Entity Interactive Data Current Entity Shell Company Entity Incorporation State Country Code Entity File Number Security 12g Title Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Prepaid expenses and other Total current assets Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Total current liabilities Other long-term liabilities Total liabilities Commitments (Note 11) Stockholders' equity: Preferred stock, 10,000,000 shares authorized Common stock, $0.001 par value; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of March 31, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of March 31, 2021 and December 31, 2020, respectively Additional paid in capital Accumulated deficit Accumulated other comprehensive income Treasury stock Total stockholders' equity Total liabilities and stockholders' equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock shares issued Preferred stock, shares outstanding Product and Service [Axis] Revenue Total revenues Operating costs and expenses: Research and development General and administrative Total operating costs and expenses Loss from operations Other income (expense): Other income (expense) Interest income Total other income Net loss Basic and diluted loss per share Weighted-average shares of common stock outstanding, basic and diluted Beginning balance, shares Beginning balance, value Share-based expense Exercise of purchase warrants, shares Exercise of purchase warrants, value Net loss Ending balance, shares Ending balance, value Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of right of use asset Share-based expense Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable, accrued expenses and other liabilities Net cash used in operating activities Net change in cash Cash at beginning of period Cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Issuance of common stock from cashless exercise of purchase warrants Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company Impact Of Covid-19 Impact of COVID-19 Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Strategic Collaborations Significant Strategic Collaborations Property, Plant and Equipment [Abstract] Property and Equipment, net Goodwill and Intangible Assets Disclosure [Abstract] Indefinite-Lived Intangible Assets Fair Value Disclosures [Abstract] Fair Value Measurements Equity [Abstract] Stockholders' Equity Share-based Payment Arrangement [Abstract] Share-Based Expense Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Preparation of Interim Financial Statements Principles of Consolidation Basic and Diluted Net Loss per Share Recent Accounting Standards Schedule of Property and Equipment, Net Schedule of Indefinite-Lived Intangible Asset Schedule of Share-Based Compensation Expense Cash flow information regarding leases Supplemental information related to operating leases Proceeds from stock offering Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others [Line Items] Revenue Research and development expenses Prepaid expenses and other current asset Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Long-Lived Tangible Asset [Axis] Property and equipment - at cost Less accumulated depreciation Property and equipment, net Depreciation expense Goodwill, beginning balance Goodwill impairment Goodwill, ending balance Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Line Items] Impairment charge Financial instruments fair value Warrants outstanding Warrants weighted average exercise price Warrant expiration dates EX-101.PRE 10 xbio-20200331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 07, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	XBIO
Entity Registrant Name	Xenetic Biosciences, Inc.
Entity Central Index Key	0001534525
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		8,746,692
Current Reporting Status	Yes
Entity Small Business	true
Entity Emerging Growth	false
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Incorporation State Country Code	NV
Entity File Number	001-37937
Security 12g Title	Common Stock, $0.001 par value per share

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 10,008,364	$ 11,527,552
Prepaid expenses and other	1,027,749	841,958
Total current assets	11,036,113	12,369,510
Other assets	725,509	809,985
Total assets	11,761,622	13,179,495
Current liabilities:
Accounts payable	207,811	327,396
Accrued expenses and other current liabilities	590,380	609,532
Total current liabilities	798,191	936,928
Other long-term liabilities	17,568	27,043
Total liabilities	815,759	963,971
Commitments (Note 11)
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized	2,774	2,774
Common stock, $0.001 par value; 50,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 8,773,683 and 8,772,198 shares issued as of March 31, 2021 and December 31, 2020, respectively; 8,746,692 and 8,745,207 shares outstanding as of March 31, 2021 and December 31, 2020, respectively	8,772	8,771
Additional paid in capital	194,209,794	194,133,511
Accumulated deficit	(178,248,031)	(176,902,086)
Accumulated other comprehensive income	253,734	253,734
Treasury stock	(5,281,180)	(5,281,180)
Total stockholders' equity	10,945,863	12,215,524
Total liabilities and stockholders' equity	11,761,622	13,179,495
Preferred Class B [Member]
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized	1,804	1,804
Preferred Class A [Member]
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized	$ 970	$ 970

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Common stock, par value	$ 0.001	$ .001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	8,773,683	8,772,198
Common stock, shares outstanding	8,746,692	8,745,207
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Class B [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares issued	1,804,394	1,804,394
Preferred stock, shares outstanding	1,804,394	1,804,394
Preferred Class A [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock shares issued	970,000	970,000
Preferred stock, shares outstanding	970,000	970,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total revenues	$ 191,216	$ 56,749
Operating costs and expenses:
Research and development	(629,729)	(359,651)
General and administrative	(930,578)	(927,880)
Total operating costs and expenses	(1,560,307)	(1,287,531)
Loss from operations	(1,369,091)	(1,230,782)
Other income (expense):
Other income (expense)	884	(134)
Interest income	22,262	51,487
Total other income	23,146	51,353
Net loss	$ (1,345,945)	$ (1,179,429)
Basic and diluted loss per share	$ (0.15)	$ (0.19)
Weighted-average shares of common stock outstanding, basic and diluted	8,746,263	6,233,331
Royalty [Member]
Revenue
Total revenues	$ 191,216	$ 56,749

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income / Loss	Treasury Stock	Total
Beginning balance, shares at Dec. 31, 2019	2,774,394	6,092,432
Beginning balance, value at Dec. 31, 2019	$ 2,774	$ 6,092	$ 188,240,451	$ (166,008,620)	$ 253,734	$ (5,281,180)	$ 17,213,251
Share-based expense			165,598				165,598
Exercise of purchase warrants, shares		219,474
Exercise of purchase warrants, value		$ 219	(219)
Net loss				(1,179,429)			(1,179,429)
Ending balance, shares at Mar. 31, 2020	2,774,394	6,311,906
Ending balance, value at Mar. 31, 2020	$ 2,774	$ 6,311	188,405,830	(167,188,049)	253,734	(5,281,180)	16,199,420
Beginning balance, shares at Dec. 31, 2020	2,774,394	8,772,198
Beginning balance, value at Dec. 31, 2020	$ 2,774	$ 8,771	194,133,511	(176,902,086)	253,734	(5,281,180)	12,215,524
Share-based expense			76,284				76,284
Exercise of purchase warrants, shares		1,485
Exercise of purchase warrants, value		$ 1	(1)
Net loss				(1,345,945)			(1,345,945)
Ending balance, shares at Mar. 31, 2021	2,774,394	8,773,683
Ending balance, value at Mar. 31, 2021	$ 2,774	$ 8,772	$ 194,209,794	$ (178,248,031)	$ 253,734	$ (5,281,180)	$ 10,945,863

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,345,945)	$ (1,179,429)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	0	591
Amortization of right of use asset	8,413	6,824
Share-based expense	76,284	165,598
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(109,728)	(86,448)
Accounts payable, accrued expenses and other liabilities	(148,212)	92,144
Net cash used in operating activities	(1,519,188)	(1,000,720)
Net change in cash	(1,519,188)	(1,000,720)
Cash at beginning of period	11,527,552	10,367,920
Cash at end of period	10,008,364	9,367,200
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	0	0
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock from cashless exercise of purchase warrants	$ 1	$ 219

XML 17 R7.htm IDEA: XBRL DOCUMENT

1. The Company

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company

1.	The Company

Background

Going Concern and Management’s Plan

XML 18 R8.htm IDEA: XBRL DOCUMENT

2. Impact of COVID-19

3 Months Ended

Mar. 31, 2021

Impact Of Covid-19

Impact of COVID-19

2.	Impact of COVID-19

XML 19 R9.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3.	Summary of Significant Accounting Policies

Preparation of Interim Financial Statements

Principles of Consolidation

Basic and Diluted Net Loss per Share

Recent Accounting Standards

XML 20 R10.htm IDEA: XBRL DOCUMENT

4. Significant Strategic Collaborations

3 Months Ended

Mar. 31, 2021

Significant Strategic Collaborations

Significant Strategic Collaborations

4.	Significant Strategic Collaborations

XML 21 R11.htm IDEA: XBRL DOCUMENT

5. Property and Equipment, net

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment, net

5.	Property and Equipment, net

Property and equipment, net consists of the following:

	March 31, 2021			December 31, 2020
Office and computer equipment	$	42,289		$	42,289
Furniture and fixtures		14,738			14,738
Property and equipment – at cost		57,027			57,027
Less accumulated depreciation		(57,027	)		(57,027	)
Property and equipment – net	$	–		$	–

Depreciation expense was approximately $1,000 for the three months ended March 31, 2020. There was no depreciation expense for the three months ended March 31, 2021.

XML 22 R12.htm IDEA: XBRL DOCUMENT

6. Indefinite-Lived Intangible Assets

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Indefinite-Lived Intangible Assets

6.	Indefinite-Lived Intangible Assets

Balance as of January 1, 2020	$	9,243,128
Impairment		(9,243,128	)
Balance as of December 31, 2020	$	–

XML 23 R13.htm IDEA: XBRL DOCUMENT

7. Fair Value Measurements

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

7.	Fair Value Measurements

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

8. Stockholders' Equity

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Equity

8.	Stockholders’ Equity

Warrants

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

9. Share-Based Expense

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Expense

9.	Share-Based Expense

Total share-based expense related to stock options and restricted stock units (“RSUs”) was approximately $0.1 and $0.2 million during the three months ended March 31, 2021 and 2020, respectively.

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:

	Three Months Ended March 31,
	2021		2020
Research and development expenses	$	10,710	$	13,358
General and administrative expenses		65,574		152,240
	$	76,284	$	165,598

Employee Stock Options

Non-Employee Stock Options

XML 26 R16.htm IDEA: XBRL DOCUMENT

10. Income Taxes

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

10.

Income Taxes

As of March 31, 2021 and December 31, 2020, the Company did not record any unrecognized tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

11. Commitments

3 Months Ended

Mar. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments

11.

Commitments

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

	Three Months Ended March 31,
	2021
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	8,413

Supplemental balance sheet information related to our operating leases are as follows:

	Balance Sheet Classification	March 31, 2021
Right-of-use assets - ST	Prepaid expenses and other	$	36,545
Right-of-use assets - LT	Other assets	$	17,568
Current lease liabilities	Accrued expenses and other current liabilities	$	36,545
Non-current lease liabilities	Other long-term liabilities	$	17,568

XML 28 R18.htm IDEA: XBRL DOCUMENT

12. Related Party Transactions

3 Months Ended

Mar. 31, 2021

Related Party Transactions

12.

Related Party Transactions

XML 29 R19.htm IDEA: XBRL DOCUMENT

13. Subsequent Events

3 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

13.

Subsequent Events

XML 30 R20.htm IDEA: XBRL DOCUMENT

3. Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Preparation of Interim Financial Statements	*Preparation of Interim Financial Statements* The accompanying condensed consolidated interim financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all normal and recurring adjustments necessary to present fairly the results of the interim periods shown. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such SEC rules and regulations. Management believes that the disclosures made are adequate to make the information presented not misleading. The results for the interim periods are not necessarily indicative of results for the full year. The condensed consolidated financial statements contained herein should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 16, 2021 and amended on April 28, 2021.
Principles of Consolidation	*Principles of Consolidation* The condensed consolidated financial statements of the Company include the accounts of Hesperix, Xenetic UK and Xenetic UK’s wholly owned subsidiaries: Lipoxen, Xenetic Bioscience, Incorporated, and SymbioTec. All intercompany balances and transactions have been eliminated in consolidation.
Basic and Diluted Net Loss per Share	*Basic and Diluted Net Loss per Share* The Company computes basic net loss per share by dividing net loss applicable to common stockholders by the weighted-average number of shares of the Company’s common stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive. For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share are the same for each respective period due to the Company’s net loss position. Potentially dilutive, non-participating securities have not been included in the calculations of diluted net loss per share, as their inclusion would be anti-dilutive.
Recent Accounting Standards	*Recent Accounting Standards* In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. This may result in earlier recognition of allowance for losses. ASU 2016-13 is effective for smaller reporting public entities for fiscal years beginning after December 15, 2022 but early adoption is permitted. The Company is currently evaluating the impact of adoption, but it does not anticipate that it will have a material effect on the Company’s consolidated financial statements.

XML 31 R21.htm IDEA: XBRL DOCUMENT

5. Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net consists of the following:

	March 31, 2021			December 31, 2020
Office and computer equipment	$	42,289		$	42,289
Furniture and fixtures		14,738			14,738
Property and equipment – at cost		57,027			57,027
Less accumulated depreciation		(57,027	)		(57,027	)
Property and equipment – net	$	–		$	–

XML 32 R22.htm IDEA: XBRL DOCUMENT

6. Indefinite-Lived Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Indefinite-Lived Intangible Asset

A reconciliation of the change in the carrying value of Indefinite-Lived Intangible Assets is as follows:

Balance as of January 1, 2020	$	9,243,128
Impairment		(9,243,128	)
Balance as of December 31, 2020	$	–

XML 33 R23.htm IDEA: XBRL DOCUMENT

9. Share-Based Expense (Tables)

3 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation Expense

Share-based compensation expense is classified in the condensed consolidated statements of operations as follows:

	Three Months Ended March 31,
	2021		2020
Research and development expenses	$	10,710	$	13,358
General and administrative expenses		65,574		152,240
	$	76,284	$	165,598

XML 34 R24.htm IDEA: XBRL DOCUMENT

11. Commitments (Tables)

3 Months Ended

Mar. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Cash flow information regarding leases

Supplemental cash flow information and non-cash activity related to our operating leases are as follows:

	Three Months Ended March 31,
	2021
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$	8,413

Supplemental information related to operating leases

Supplemental balance sheet information related to our operating leases are as follows:

	Balance Sheet Classification	March 31, 2021
Right-of-use assets - ST	Prepaid expenses and other	$	36,545
Right-of-use assets - LT	Other assets	$	17,568
Current lease liabilities	Accrued expenses and other current liabilities	$	36,545
Non-current lease liabilities	Other long-term liabilities	$	17,568

XML 35 R25.htm IDEA: XBRL DOCUMENT

1. The Company (Details Narrative)	11 Months Ended
1. The Company (Details Narrative)	Dec. 04, 2020 USD ($)
Direct Offering [Member]
Proceeds from stock offering	$ 5,400,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

4. Significant Strategic Collaborations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	$ 191,216	$ 56,749
Research and development expenses	629,729	359,651
Prepaid expenses and other current asset	1,027,749		$ 841,958
Pharmsynthez [Member] \| Sponsored Research Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expenses	100,000
Prepaid expenses and other current asset	200,000		$ 200,000
Takeda [Member] \| Royalty [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	200,000	100,000
Serum Institute [Member] \| Royalty [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	0	0
SynBio [Member] \| Royalty [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue	0	$ 0
Scripps [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expenses	$ 1,200,000

XML 37 R27.htm IDEA: XBRL DOCUMENT

5. Property and Equipment, net (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment - at cost	$ 57,027	$ 57,027
Less accumulated depreciation	(57,027)	(57,027)
Property and equipment, net	0	0
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment - at cost	42,289	42,289
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment - at cost	$ 14,738	$ 14,738

XML 38 R28.htm IDEA: XBRL DOCUMENT

5. Property and Equipment, net (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 591

XML 39 R29.htm IDEA: XBRL DOCUMENT

6. Indefinite-Lived Intangible Assets (Details)	3 Months Ended
6. Indefinite-Lived Intangible Assets (Details)	Mar. 31, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, beginning balance	$ 9,243,128
Goodwill impairment	(9,243,128)
Goodwill, ending balance	$ 0

XML 40 R30.htm IDEA: XBRL DOCUMENT

6. Indefinite-Lived Intangible Assets (Details Narrative)	3 Months Ended
	Sep. 30, 2020 USD ($)
OncoHist [Member]
Indefinite-lived Intangible Assets [Line Items]
Impairment charge	$ 9,200,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

7. Fair Value Measurements (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Fair Value Inputs Level 3 [Member]
Financial instruments fair value	$ 0	$ 0

XML 42 R32.htm IDEA: XBRL DOCUMENT

8. Stockholders' Equity (Details Narrative) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Colllaboration Warrants [Member]
Warrants outstanding	30,307		30,307
Warrants weighted average exercise price	$ 124.74		$ 124.74
Warrant expiration dates	April 2021 through May 2021
Warrants granted	0	0
Warrants exercised	0	0
Debt and Equity Financing Warrants [Member]
Warrants outstanding	347,505		378,453
Warrants weighted average exercise price	$ 36.74		$ 36.74
Warrant expiration dates	July 2021 through September 2026
Warrants exercised	1,485	200,000
Warrants expired	29,000	0

XML 43 R33.htm IDEA: XBRL DOCUMENT

9. Share-Based Expense (Details - Share based expense) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based compensation	$ 76,284	$ 165,598
Research and Development Expense [Member]
Share-based compensation	10,710	13,358
General and Administrative Expense [Member]
Share-based compensation	$ 65,574	$ 152,240

XML 44 R34.htm IDEA: XBRL DOCUMENT

9. Share-Based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based compensation expense	$ 76,284	$ 165,598
Restricted Stock Units (RSUs) [Member]
Share-based compensation expense	100,000	$ 200,000
Options granted		0
Employee Stock Options [Member]
Share-based compensation expense	$ 100,000	$ 200,000
Options granted	200,000	0
Weighted average grant date fair value	$ 2.34
Risk free rate	1.08%
Expected term	5 years 10 months 17 days
Volatility rate	134.47%
Options exercised	0
Non Employee Stock Options [Member]
Share-based compensation expense	$ 0	$ 4,000
Options granted	0	0
Options exercised	0	0
Options expired	0	0

XML 45 R35.htm IDEA: XBRL DOCUMENT

10. Income Taxes (Details Narrative) - USD ($)	3 Months Ended
10. Income Taxes (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0
Deferred tax valuation allowance	29,900,000		$ 29,600,000
Unrecognized tax positions	$ 0		$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 46 R36.htm IDEA: XBRL DOCUMENT

11. Commitments (Details - Cash flow Information)	3 Months Ended
11. Commitments (Details - Cash flow Information)	Mar. 31, 2021 USD ($)
Operating cash flow information:
Cash paid for amounts included in the measurement of lease liabilities	$ 8,413

XML 47 R37.htm IDEA: XBRL DOCUMENT

11. Commitments (Details - lease information)	Mar. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets, current	$ 36,545
Right-of-use assets, non-current	17,568
Current lease liabilities	36,545
Non-current lease liabilities	$ 17,568

XML 48 R38.htm IDEA: XBRL DOCUMENT

12. Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2020
Research and development expense	$ 629,729	$ 359,651
Prepaid expenses and other current asset	1,027,749			$ 841,958
Related Party Cost	100,000
Research expense accrued	590,380			609,532
Pharmsynthez [Member] \| Co-Development Agreement [Member]
Payment for note receivable			$ 500,000
Note receivable outstanding	$ 500,000
Note receivable interest rate	10.00%
Interest income	$ 12,000	$ 13,000
Pharmsynthez [Member] \| Sponsored Research Agreement [Member]
Research and development expense	100,000
Payment for research agreement			$ 350,000
Prepaid expenses and other current asset	200,000			200,000
Advanced payment				25,000
Pharmsynthez [Member] \| Sponsored Research Agreement [Member] \| Prepaid expenses and other [Member]
Prepaid expenses and other current asset	500,000			$ 500,000
Research expense accrued	$ 30,000

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 92 210 1 false 30 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://xeneticbio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://xeneticbio.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://xeneticbio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://xeneticbio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements Of Stockholders' Equity (Unaudited) Sheet http://xeneticbio.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements Of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://xeneticbio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - 1. The Company Sheet http://xeneticbio.com/role/Company 1. The Company Notes 7 false false R8.htm 00000008 - Disclosure - 2. Impact of COVID-19 Sheet http://xeneticbio.com/role/ImpactOfCovid-19 2. Impact of COVID-19 Notes 8 false false R9.htm 00000009 - Disclosure - 3. Summary of Significant Accounting Policies Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies 3. Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - 4. Significant Strategic Collaborations Sheet http://xeneticbio.com/role/SignificantStrategicCollaborations 4. Significant Strategic Collaborations Notes 10 false false R11.htm 00000011 - Disclosure - 5. Property and Equipment, net Sheet http://xeneticbio.com/role/PropertyAndEquipmentNet 5. Property and Equipment, net Notes 11 false false R12.htm 00000012 - Disclosure - 6. Indefinite-Lived Intangible Assets Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssets 6. Indefinite-Lived Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - 7. Fair Value Measurements Sheet http://xeneticbio.com/role/FairValueMeasurements 7. Fair Value Measurements Notes 13 false false R14.htm 00000014 - Disclosure - 8. Stockholders' Equity Sheet http://xeneticbio.com/role/StockholdersEquity 8. Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - 9. Share-Based Expense Sheet http://xeneticbio.com/role/Share-basedExpense 9. Share-Based Expense Notes 15 false false R16.htm 00000016 - Disclosure - 10. Income Taxes Sheet http://xeneticbio.com/role/IncomeTaxes 10. Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - 11. Commitments Sheet http://xeneticbio.com/role/Commitments 11. Commitments Notes 17 false false R18.htm 00000018 - Disclosure - 12. Related Party Transactions Sheet http://xeneticbio.com/role/RelatedPartyTransactions 12. Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - 13. Subsequent Events Sheet http://xeneticbio.com/role/SubsequentEvents 13. Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - 3. Summary of Significant Accounting Policies (Policies) Sheet http://xeneticbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies 3. Summary of Significant Accounting Policies (Policies) Policies http://xeneticbio.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - 5. Property and Equipment, net (Tables) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetTables 5. Property and Equipment, net (Tables) Tables http://xeneticbio.com/role/PropertyAndEquipmentNet 21 false false R22.htm 00000022 - Disclosure - 6. Indefinite-Lived Intangible Assets (Tables) Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables 6. Indefinite-Lived Intangible Assets (Tables) Tables http://xeneticbio.com/role/Indefinite-livedIntangibleAssets 22 false false R23.htm 00000023 - Disclosure - 9. Share-Based Expense (Tables) Sheet http://xeneticbio.com/role/Share-basedExpenseTables 9. Share-Based Expense (Tables) Tables http://xeneticbio.com/role/Share-basedExpense 23 false false R24.htm 00000024 - Disclosure - 11. Commitments (Tables) Sheet http://xeneticbio.com/role/CommitmentsTables 11. Commitments (Tables) Tables http://xeneticbio.com/role/Commitments 24 false false R25.htm 00000025 - Disclosure - 1. The Company (Details Narrative) Sheet http://xeneticbio.com/role/CompanyDetailsNarrative 1. The Company (Details Narrative) Details http://xeneticbio.com/role/Company 25 false false R26.htm 00000026 - Disclosure - 4. Significant Strategic Collaborations (Details Narrative) Sheet http://xeneticbio.com/role/SignificantStrategicCollaborationsDetailsNarrative 4. Significant Strategic Collaborations (Details Narrative) Details http://xeneticbio.com/role/SignificantStrategicCollaborations 26 false false R27.htm 00000027 - Disclosure - 5. Property and Equipment, net (Details) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetDetails 5. Property and Equipment, net (Details) Details http://xeneticbio.com/role/PropertyAndEquipmentNetTables 27 false false R28.htm 00000028 - Disclosure - 5. Property and Equipment, net (Details Narrative) Sheet http://xeneticbio.com/role/PropertyAndEquipmentNetDetailsNarrative 5. Property and Equipment, net (Details Narrative) Details http://xeneticbio.com/role/PropertyAndEquipmentNetTables 28 false false R29.htm 00000029 - Disclosure - 6. Indefinite-Lived Intangible Assets (Details) Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetails 6. Indefinite-Lived Intangible Assets (Details) Details http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - 6. Indefinite-Lived Intangible Assets (Details Narrative) Sheet http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsDetailsNarrative 6. Indefinite-Lived Intangible Assets (Details Narrative) Details http://xeneticbio.com/role/Indefinite-livedIntangibleAssetsTables 30 false false R31.htm 00000031 - Disclosure - 7. Fair Value Measurements (Details Narrative) Sheet http://xeneticbio.com/role/FairValueMeasurementsDetailsNarrative 7. Fair Value Measurements (Details Narrative) Details http://xeneticbio.com/role/FairValueMeasurements 31 false false R32.htm 00000032 - Disclosure - 8. Stockholders' Equity (Details Narrative) Sheet http://xeneticbio.com/role/StockholdersEquityDetailsNarrative 8. Stockholders' Equity (Details Narrative) Details http://xeneticbio.com/role/StockholdersEquity 32 false false R33.htm 00000033 - Disclosure - 9. Share-Based Expense (Details - Share based expense) Sheet http://xeneticbio.com/role/Share-basedExpenseDetails-ShareBasedExpense 9. Share-Based Expense (Details - Share based expense) Details http://xeneticbio.com/role/Share-basedExpenseTables 33 false false R34.htm 00000034 - Disclosure - 9. Share-Based Compensation (Details Narrative) Sheet http://xeneticbio.com/role/Share-basedCompensationDetailsNarrative 9. Share-Based Compensation (Details Narrative) Details 34 false false R35.htm 00000035 - Disclosure - 10. Income Taxes (Details Narrative) Sheet http://xeneticbio.com/role/IncomeTaxesDetailsNarrative 10. Income Taxes (Details Narrative) Details http://xeneticbio.com/role/IncomeTaxes 35 false false R36.htm 00000036 - Disclosure - 11. Commitments (Details - Cash flow Information) Sheet http://xeneticbio.com/role/CommitmentsDetails-CashFlowInformation 11. Commitments (Details - Cash flow Information) Details http://xeneticbio.com/role/CommitmentsTables 36 false false R37.htm 00000037 - Disclosure - 11. Commitments (Details - lease information) Sheet http://xeneticbio.com/role/CommitmentsDetails-LeaseInformation 11. Commitments (Details - lease information) Details http://xeneticbio.com/role/CommitmentsTables 37 false false R38.htm 00000038 - Disclosure - 12. Related Party Transactions (Details Narrative) Sheet http://xeneticbio.com/role/RelatedPartyTransactionsDetailsNarrative 12. Related Party Transactions (Details Narrative) Details http://xeneticbio.com/role/RelatedPartyTransactions 38 false false All Reports Book All Reports xbio-20200331.xml xbio-20200331.xsd xbio-20200331_cal.xml xbio-20200331_def.xml xbio-20200331_lab.xml xbio-20200331_pre.xml http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 true true ZIP 54 0001683168-21-001893-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-001893-xbrl.zip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end